Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Goserelin

Antineoplastic Agents, Hormonal

Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.

Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.

3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.

GnRHa

XIANGYUN ZONG, MD, PhD

This prospective randomized controlled study is conducted to analyze the effect of Goserelin on ovarian function in women with breast cancer in China.

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China

The serum levels of anti-Müllerian hormone (AMH) were measured using human AMH ELISA kit (11351, Biofine)). POI (premature ovarian insufficiency) was defined as AMH\<0.5ng/mL in this study.

Zhejiang Cancer Hospital

Xiangyun Zong

Chief

Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.

GnRHa: 3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.

GnRHa Group

None GnRHa Group

Eligible patients with breast cancer treated with Gonadotrophin-releasing hormone analogues （GnRHa） while receiving chemotherapy.

Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.

GnRHa (Gonadotrophin-releasing Hormone Analogues) Group

None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

CHINA

Race/Ethnicity, Customized

China

Region of Enrollment

anti-Müllerian hormone (AMH)

Dr. ZONG

Eligible patients with breast cancer treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.

Goserelin 3.6mg, or leuprorelin 3.75mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.

Eligible patients with breast cancer treated without GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy.

Spots Global Cancer Trial Database for Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial